New Immune-Blocking Injection Will Prevent Hair Loss by Silencing Harmful Inflammation Signals
SinoMab BioScience has presented promising preclinical data for its Anti-CGC Antibody (hC2) at the Society for Investigative Dermatology (SID) 2026 Annual Meeting. In humanized animal models of alopecia areata, hC2 administration significantly reduced hair loss by blocking the common gamma chain receptor, which acts as the main gateway for inflammatory cytokines.
